Zug, Switzerland, May 22, 2015 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will release its financial results for the first quarter 2015, on Thursday, May 28, 2015. Following the announcement, Auris Medical's management will host a live conference call and webcast at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time) to discuss Auris Medical's financial results for the first quarter 2015 and provide a general business update.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Auris Medical Q1 2015 Announcement http://hugin.info/160190/R/1923474/689768.pdf
CONTACT: Auris Medical Holding AG Bahnhofstrasse 21 CH-6300 Zug Tel. +41 41 729 71 94 www.aurismedical.com
Source:Auris Medical AG